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We evaluated the effects of the bisphosphonate pamidronate
on bone histomorphometry, structure and strength in male
rats with uninephrectomy or with chronic renal disease
induced by 5/6 nephrectomy. In rats with chronic renal
disease the plasma urea, phosphate and parathyroid
hormone levels were significantly increased compared to rats
with a uninephroctomy and none of these parameters was
affected by pamidronate treatment. In the femoral midshaft,
chronic renal disease reduced cortical bone mineral density
and content. No difference was observed in the breaking
load of the femoral midshaft. In the distal femur, a high-
turnover renal osteodystrophy was found but pamidronate
suppressed this bone turnover and increased bone mineral
content. Treatment had no effect on chronic disease-induced
augmentation of osteoid volume or fibroblast surface. These
studies show that in this model of stage 3 renal disease,
pamidronate increased mineral content in the femoral
midshaft and distal metaphysis primarily by adding bone to
endocortical and trabecular surfaces but did not reduce
osteitis fibrosa.
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Chronic renal insufficiency (CRI) is associated with abnor-
mal bone and mineral metabolism (chronic kidney disease
(CKD)–mineral and bone disorder).1,2 Patients with CRI
frequently develop secondary hyperparathyroidism, which
increases the risk of high-turnover bone disease. Bispho-
sphonates are commonly used for the treatment of high
turnover bone diseases. At the tissue level, the mechanism of
action of bisphosphonates is to inhibit bone resorption,
which in turn results in reduced bone turnover.3,4 Bispho-
sphonate treatment has been shown to ameliorate the
abnormal histological appearance of bone in moderate
experimental CRI5 and to be effective in preserving bone
mineral density (BMD) in populations with CRI6,7 and in
hemodialysis patients.8,9 However, dual-energy X-ray absorp-
tiometry (DXA) measurements do not comprehensively
address tissue- and organ-level changes in bone1,2,10 and
data on the effects of bisphosphonates on bone structure and
fragility in CRI are completely lacking.6,11 Furthermore, some
patients with CRI have low bone turnover,12 whereupon use
of bisphosphonates could result in excessive suppression of
bone turnover, which in turn may predispose to adynamic
bone disease and increased bone fragility.13–15 For the
present, the effect of bisphosphonates in the treatment of
CKD–mineral and bone disorder is unknown, and thus use of
bisphosphonates in patients with severely impaired renal
function cannot be justified. However, further exploration
has been recommended.10,11
The purpose of this experimental study was to determine
the effects of pamidronate (APD; 3-amino-1-hydroxypropy-
lidene-1,1-biphosphonate), an amino-substituted, second-
generation bisphosphonate, on mild-to-moderate (stage 3)
CRI-induced structural changes in the growing skeleton.
Since a vital task of the skeleton is to facilitate locomotion
and bear incident loads without breaking,1,16–18 we chose an
organ-level approach to examine experimental CKD.19–21
This structurally oriented evaluation of CRI-induced skeletal
changes focused on two distinct regions of rat femur: (1) the
femoral midshaft, a virtually pure tubular cortical bone
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structure, and (2) the distal femur, a bone region occupied
largely by trabecular bone.
RESULTS
Gross characteristics and plasma chemistry
Two CRI rats were lost during the disease progression period
and two CRIþAPD rats were lost during the treatment
period (Figure 1). These animals were not included in the
analyses. Neither the present model of CRI induced by 5/6
nephrectomy, nor APD treatment, significantly influenced
body weights in the study groups (Table 1). CRI resulted in
the anticipated biochemical effects: plasma creatinine was
increased 1.5-fold, urea 1.8-fold, phosphate 1.4-fold, and
parathyroid hormone (PTH) fivefold when compared with
the Uni-Nx Control group. These biochemical variables were
not affected by the 8-week APD treatment. Plasma creatinine,
phosphate and PTH levels did not differ between the Uni-Nx
Control group and age-matched normal Sprague–Dawley rats
(Control group; Table 1), confirming that the unilateral
nephrectomy did not result in the development of renal
insufficiency. However, plasma calcitriol concentration was
lower in the Uni-Nx Control group when compared with that
in the age-matched controls. This decrease in calcitriol level
was not observed in groups treated with APD (Table 1).
Effects of experimental renal insufficiency on the femur
The present model of CRI resulted in the characteristic
histomorphometric features of renal osteodystrophy in the
distal femoral metaphysis, including increased bone turnover
(resorption and formation) and peritrabecular bone marrow
fibrosis (osteitis fibrosa) (Table 2; Figure 2). Specifically, CRI
increased eroded bone surface (ES/BS), double labeled bone
surface (dL.S/BS), mineral apposition rate (MAR), bone
formation rate (BFR/BS), osteoid surface (OS/BS), and
osteoid volume (OV/BV). In addition to increasing turnover,
CRI increased peritrabecular fibroblast-lined bone surface
(Fb.S/BS).
In a site-specific analysis of cortical bone structure using
peripheral quantitative computed tomography (pQCT), CRI
resulted in loss of mineral, seen as decreased volumetric bone
mineral density of the femoral midshaft (cortical bone
mineral density (cBMD); P¼ 0.003 for the main effect;
Figure 3a), whereas no significant changes with CRI were
observed in bone size (cross-sectional area (CSA)) or cortical
area (Figure 3b and c), and thereupon, bone mineral content
(BMC) in the midshaft was decreased (5%, P¼ 0.035, CRI
versus Uni-Nx Control; Figure 3e). CRI did not affect the
outer and inner diameters of the bone of the femoral
midshaft and an insignificant trend for decrease was observed
in the breaking load in three-point bending (Figure 3f). In
the distal femur, no significant CRI-associated effects were
observed in BMC or CSA (Figure 4).
Effects of pamidronate treatment on the femur
APD treatment was associated with an increase in cancellous
bone mass due to dramatic suppression of bone turnover
(Table 2). Clear improvements were observed in the
trabecular architecture of the distal femoral metaphysis;
APD resulted in increased bone volume normalized to tissue
volume (BV/TV), trabecular thickness (Tb.Th), and trabe-
cular number (Tb.N), and a corresponding decrease in
trabecular separation (Tb.Sp) (Table 2; Figure 2). Severe
osteomalacia was observed in one APD-treated CRI rat
n=12
n=33
UNI-Nx control
CRI
Surgery Progression Treatment
0 8 22 30
Weeks
Control (n=12)
UNI-Nx control (n=7)
UNI-Nx+APD (n=6)
CRI (n=8)
CRI+APD (n=6)
Figure 1 | Flowchart of the study. Control, age-matched normal
group; Uni-Nx, subjected to unilateral nephrectomy; APD,
pamidronate treatment; CRI, chronic renal insufficiency group
subjected to 5/6 nephrectomy.
Table 1 | Body weight and results of the plasma chemistry after APD treatment
ANOVA
Uni-Nx Control Uni-Nx+APD CRI CRI+APD CRI APD Control
Number of animals 7 6 8 6 12
Body weight (g)
Baseline (8 weeks) 271±8 264±8 279±7 272±8 NS NS
30 weeks 513±17 492±13 540±18 498±17 NS NS 501±10
Plasma (30 weeks)
Creatinine (mmol/l) 57.0±2.0 59.8±3.6 88.5±12.3 92.0±17.5 Po0.05 NS 56.7±1.5
Urea (mmol/l) 6.8±0.3 7.2±0.5 12.3±1.7 12.4±1.9 Po0.05 NS 5.8±0.7
Phosphate (mmol/l) 1.30±0.14 1.20±0.08 1.79±0.20 1.59±0.15 Po0.05 NS 1.17±0.05
PTH (pg/ml) 102±22 94±20 501±167 442±286 Po0.05 NS 135±31
Calcitriol (pmol/l) 134±12 229±33 124±19 193±38 NS Po0.05 233±32a
ANOVA, analysis of variance; APD, pamidronate; Control, age-matched control group; CRI, chronic renal insufficiency group subjected to 5/6 nephrectomy; NS, statistically
non-significant difference; PTH, parathyroid hormone; Uni-Nx Control, group subjected to unilateral nephrectomy.
Data are mean±s.e.m.; aPo0.05 versus Uni-Nx Control (one-way ANOVA).
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(Figure 2). APD inhibited indices of bone turnover in Uni-
Nx Control and CRI rats, including Ob.S/BS, ES/BS, dL.S/BS,
MAR, and BFR/BS (Table 2). Interestingly, APD increased
Oc.S/BS. However, the osteoclasts in APD-treated rats
were condensed and often detached from the bone surface.
APD had no significant effect on OS/BS, OV/BV, OV/TV,
or Fb.S/BS.
In the DXA analysis of the entire femur, APD signifi-
cantly increased BMC (Po0.002 for the main effect;
Figure 5). This treatment effect was particularly observed in
the CRI animals (þ 10%, P¼ 0.003, CRIþAPD versus CRI;
Figure 5).
In the pQCT analysis of the femoral midshaft, APD did
not affect the cortical volumetric density (cBMD; Figure 3a),
but the treatment resulted in decreased CSA (P¼ 0.016 for
the main effect; Figure 3b). In the CRI animals, APD
increased cortical area (þ 9%, P¼ 0.026, CRIþAPD versus
CRI; Figure 3c) and BMC (þ 8%, P¼ 0.012, CRIþAPD
versus CRI; Figure 3e). Following APD treatment, the area of
the marrow cavity decreased (Figure 6) and average cortical
thickness increased (Po0.012 for the main effect; Figure 3d).
These changes were not associated with any difference in the
breaking load of the femur midshaft (Figure 3f).
In the distal femur, APD treatment resulted in increased
BMC (Po0.001 for the main effect; Figure 4a). No
differences between the study groups were observed regarding
the size of the distal femoral bone (CSA; Figure 4b). A pQCT
image from the distal femur of each study animal is shown in
Figure 7.
DISCUSSION
The effects of bisphosphonate treatment have been studied in
various skeletal diseases that are characterized by increased
bone resorption, including CKD,5–9,22 post renal-transplant
bone disease,23–27 mild primary hyperparathyroidism,28
Paget’s disease of the bone,29 osteogenesis imperfecta,30,31
myeloma, bone metastases, and most importantly, in the
prevention and treatment of postmenopausal osteoporo-
sis.32–34 Bisphosphonates can also be used in the prevention
of vascular calcification.22,35 However, use of bisphoshonates
in CKD is an unsolved issue at the present and concern has
been raised as treatment could increase the risk of potentially
pernicious adynamic bone disease12–15 and hinder bone
mechanical integrity.36 In this study, we examined the effects
of APD on bone using a model of CRI in a growing skeleton.
As expected, APD suppressed bone turnover. We did not
observe any adverse effects on mineral accrual or mechanical
integrity of cortical bone. In agreement with the known
mechanism of action of bisphosphonates (that is, inhibiting
bone resorption), the treatment effect of APD was observed
in the regions of the bone with highest metabolic activity,
that is the distal femoral metaphysis and endocortical surface
Table 2 | Bone histomorphometry for the distal femur metaphysis after APD treatment
ANOVA
Uni-Nx Control Uni-Nx+APD CRI CRI+APD CRI APD Interaction
BV/TV (%) 8.0±1.6 20.9±1.9 7.4±1.5 17.9±1.6 NS Po0.001 NS
Tb.Th (mm) 56.3±4.9 77.2±5.8 54.1±4.6 77.3±4.9 NS Po0.001 NS
Tb.N (mm1) 1.37±0.19 2.74±0.23 1.33±0.18 2.28±0.19 NS Po0.001 NS
Tb.Sp (mm) 771±109 294±129 807±102 401±109 NS Po0.001 NS
ES/BS (%) 1.9±0.4 0.5±0.3a 5.1±1.1a 0.1±0.1b P=0.046 Po0.001 P=0.013
dL.S/BS (%) 21.4±1.5 1.0±0.6c 36.7±2.4c 1.7±0.7d Po0.001 Po0.001 Po0.001
MAR (mm/day) 1.86±0.14 0.49±0.31 2.57±0.15 1.18±0.46 P=0.038 Po0.001 NS
BFR/BS (mm2/mm/day) 0.41±0.06 0.02±0.01c 0.94±0.08c 0.05±0.02d Po0.001 Po0.001 Po0.001
OS/BS (%) 5.7±1.6 0.8±0.5 11.3±2.4 7.4±3.4 P=0.017 NS NS
OV/BV (%) 0.87±0.24 0.15±0.11 2.08±0.60 2.07±1.11 P=0.024 NS NS
OV/TV (%) 0.11±0.03 0.04±0.03 0.18±0.03 0.48±0.24 NS NS NS
Fb.S/BS (%) 0.09±0.09 0.83±0.42 6.13±2.58 7.54±2.18 P=0.002 NS NS
Ob.S/BS (%) 2.01±0.38 0.46±0.46 4.65±0.81 0.40±0.40 NS P=0.005 NS
Oc.S/BS (%) 1.26±0.43 5.02±2.06a 2.14±0.62a 5.56±1.63b P=0.046 Po0.001 P=0.039
APD, pamidronate; BFS/BS, bone formation rate/bone surface; BV/TV, bone volume/tissue volume; CRI, chronic renal insufficiency group subjected to 5/6 nephrectomy;
dL.S/BS, double labelled surface/bone surface; ES/BS, eroded surface/bone surface; Fb.S/BS, fibrosis surface/bone surface; MAR, mineral apposition rate; NS, statistically
non-significant difference; Ob.S/BS, osteoblast surface/bone surface; Oc.S/BS, osteoclast surface/bone surface; OS/BS, osteoid surface/bone surface; OV/BV, osteoid volume/
bone volume; OV/TV, osteoid volume/tissue volume; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness; Uni-Nx Control, group subjected to
unilateral nephrectomy.
Data are given as mean±s.e.m.; aPo0.05 versus Uni-Nx Control; bPo0.01 versus CRI; cPo0.001 versus Uni-Nx Control; dPo0.001 versus CRI.
a b
200 µm 200 µm
Figure 2 | Effects of CRI and APD treatment on bone
histomorphometry at the distal femoral metaphysis. (a) CRI
rat showing high-bone turnover parathyroid bone disease.
(b) APD-treated CRI rat showing low-bone turnover and increased
osteoid volume. Arrows indicate increased osteoid with
osteoblasts. Arrowheads indicate thickened osteoid with no
osteoblast-lined surface (osteomalacia).
Kidney International (2008) 74, 319–327 321
J Jokihaara et al.: Pamidronate and renal bone disease o r i g i n a l a r t i c l e
of the femoral midshaft. In addition, the interaction between
CRI and the effect of APD treatment indicated that the action
of APD was particularly evident in association with CRI-
induced metabolic challenge on cortical bone.
Our present histomorphometric analysis excluded the
primary spongiosa and focused on the secondary spongiosa
of the distal femoral metaphysis. We observed that APD
clearly decreased bone turnover to values below normal.
Osteoid volume was increased in APD-treated rats, suggest-
ing delayed mineralization, but, with the exception of one
animal, APD treatment was not associated with osteomalacia
(Table 2; Figure 2). The pQCT analysis of the distal femur
showed that APD increased BMC, without having an effect
on bone size (CSA) (Figure 4), which suggests that the
treatment resulted in increased trabecular density. This was
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Figure 3 | The femoral midshaft by pQCT and biomechanical testing. The effect of CRI and APD treatment, alone and in combination, on
cBMD (a), total bone CSA (b), cortical bone area (c), average cortical thickness (d), BMC (e), and breaking load (f). Data denotations are mean
(line) and s.e.m. (whiskers); a CRI main effect, b APD treatment effect.
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of CRI and APD treatment, alone and in combination, on BMC
using DXA. Data denotations are mean (line) and s.e.m. (whiskers).
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confirmed by histomorphometry in which relative bone
volume (BV/TV) was highly increased in both study groups
receiving APD. It was further shown that increased relative
bone volume was attributable to an increase in both
trabecular thickness and number, and consequently, a
decrease in trabecular separation (Table 2). These findings
can be explained if suppression of bone resorption by APD
exceeded the suppression of bone formation. However, we
cannot rule out the possibility that increased mineralization
contributed to the overall increase in BMC.37
Pamidronate decreased osteoblast surface, but increased
osteoclast surface. The latter is not a novel finding. It is
recognized that this class of drug can increase osteoclast
number but decrease their function.38–40 The osteoclasts in
the APD-treated rats were rounded in appearance and often
detached from the bone surface, suggesting greatly decreased
activity. This conclusion is supported by the observation that
erosion surface was decreased with APD treatment.
CRI resulted in an increase in OV/BV, but this decrease in
the quality of bone may have been imperceptible in the
biomechanical testing of the femoral midshaft, because the
defect would have been limited to remodeling bone only. CRI
resulted in mild peritrabecular bone marrow fibrosis (osteitis
fibrosa). APD treatment had no beneficial effect on reducing
Fb.S/BS or OV/BS. This finding is not surprising because
APD did not reduce the secondary hyperparathyroidism
associated with CRI.
In the cortical bone region of the femoral midshaft, CRI
was associated with decreased cBMD, suggesting increased
porosity of the cortex. Our present model of CRI resulted in
secondary hyperparathyroidism and elevated PTH levels.
Chronic infusion of PTH into rats has been shown to increase
cortical porosity due to endocortical and periosteal tunneling
by osteoclasts, suggesting that elevated PTH is responsible for
the decreased cBMD.41 Interestingly, APD treatment did not
affect cBMD (that is, the porosity of cortical bone), or PTH
levels, but was associated with decreased radial growth of
bone (CSA) and simultaneously increased cortical area. By
coupling this information with the findings that APD
reduced the inner femoral midshaft diameters and increased
average cortical thickness (Figures 3 and 6), it can be said that
these changes in the geometry of the femoral midshaft
persuasively show that the increases in BMC and cortical area
(net apposition of cortical bone) are attributable to
suppression of bone resorption at the endocortical surface
(Figure 6). However, in spite of the increase in cortical
thickness, APD administration has the potential to adversely
influence bone strength, since we found that APD treatment
was associated with decreased cross-sectional size. Never-
theless, our mechanical testing data showed that the
structural strength of the femora were maintained, but not
increased, which could be explained by the significant
deposition of mineral on the endocortical midshaft surfaces
(Figures 3 and 6). It is possible that the absence of decreased
bone strength could also be due to the moderate degree of
Mediolateral direction
APD effect P=0.011
Anteroposterior direction
APD effect P=0.012
Figure 6 | The effect of APD treatment on marrow cavity
(medullary canal) dimensions in femoral midshaft
(anteroposterior and mediolateral directions). The cortical area
in untreated animals is depicted by gray and the effect of APD
treatment is depicted by black.
UNI-Nx
Control
UNI-Nx CRI CRI
+APD +APD
Figure 7 | A set of pQCT images of distal femur of each CRI and
Uni-Nx rat showing the impact of APD treatment on bone
(the amount of white coloring reflects higher volumetric
bone mineral density).
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renal impairment and relatively small sample size. However,
this finding is consistent with the well-established theory of
functional bone adaptation,42 a loading-driven feedback
system by which bone senses the incident mechanical strain
and removes bone tissue from sites where loading is
marginal, while forming new bone tissue at sites subjected
to increased loading. This mechanism contributes to bones
being formed with mechanically appropriate size, shape,
and architecture to successfully perform their locomotive
function.16–19,42 According to the principles of biomechanics,
the expansion of bone diameter while retaining the same
amount of bone in the transverse plane (that is, a larger bone
with thinner cortex), increases the resistance of bone to
bending and torsion to the third power of the increase in
diameter.43 Thus, although the APD-induced endocortical
mineral apposition is located on the biomechanically less
optimal bone surface, it apparently also resulted in increased
bone rigidity, and subsequently, the incident strains in the
loaded bones arguably remained within limits that required
no further adaptive response, whereby the need for periosteal
apposition was also obviated.
The biochemical changes observed in this study are in
good agreement with previous reports on experimental CRI
(Table 1). The 5/6 nephrectomy resulted in several charac-
teristics of CRI, whereas unilateral nephrectomy only affected
plasma calcitriol levels, plausibly due to decreased renal mass,
whereas APD administration prevented this decrease.44 The
increase in calcitriol after APD treatment may be explained
by the lowering influence of APD administration on plasma
fibroblast growth factor-23, a known inhibitor of calcitriol
synthesis.45 Thus, decreased bone turnover could reduce the
release of fibroblast growth factor-23 from bone, which
attenuates the inhibitory effect of fibroblast growth factor-23
on calcitriol production. This mechanism remains to be
confirmed in future experiments.
Intriguingly, decreased renal function corresponding to
stage-3 CKD10 accentuated the actions of APD. The
interaction between APD treatment and CRI, observed in
total BMC of the whole femur, as well as the cortical area, the
average cortical thickness, and the BMC of the femoral
midshaft (Figures 3 and 5), suggests that the metabolic
challenge induced by the present model of CRI on bone
homeostatic control (high bone turnover) augmented the
effects of APD. Furthermore, the bone-wasting effect of CRI,
and the bone-preserving effect of APD, may be, at least
partially, mediated through distinct pathways: the deleterious
effects of CRI were primarily observed intracortically
(decreased cBMD, suggesting increased cortical bone poro-
sity; Figure 3a), whereas APD affected the amount of cortical
bone through changes on the endocortical surface (increased
cortical area and cortical thickness; Figures 3c and d, and 6).
The above findings suggesting that APD action is
principally evident on the most metabolically active bone
surfaces, and particularly in a diseased bone, are in good
agreement with results from studies on APD treatment in
children with osteogenesis imperfecta. Rauch et al.29 have
shown that APD treatment of such children increases average
cortical thickness, trabecular number, and the amount of
bone at the endocortical surface. Weber et al.31 have recently
alleviated the concern that a possible harmful influence of
APD treatment on bone material characteristics might negate
the beneficial effects of the gain in bone mass, and lead to
long-term bone fragility: APD treatment of children with
osteogenesis imperfecta did not have an adverse effect on the
intrinsic material properties of bone.
The 5/6 nephrectomized rat is the most widely used
experimental model of CRI, with the natural progression of
the disease from the characteristic serum changes into the
‘full-blown’ renal failure and the associated organ-level
manifestations.46 The rats used in this study were 8–30 weeks
of age during the experiments, and thus provided a means for
exploring the effects of bisphosphonate treatment in the
constantly, albeit slowly growing, skeleton.5,47,48 Therefore,
the results obtained from this adolescent rat model must be
interpreted prudently if extrapolated to adults. It should also
be stressed that the present model of CRI corresponds to
stage-3 CKD in humans.10 Therefore, the effects of APD
treatment on bone in more severe CRI (stage 4–5) should to
be evaluated in future experiments. Although the mechanical
strength of the bones provides the ultimate phenotype of the
skeleton, the biomechanical testing in experimental osteo-
porosis research is limited to cortical bone. Our results
suggest that cancellous bone should be evaluated in future
studies.
In conclusion, our study showed that in experimental
CKD–mineral and bone disorder, treatment with APD did
not cure osteitis fibrosa in rats with established CRI. As a
consequence, APD treatment may be more effective in
preventing fibrosis if initiated prior to development of
CKD–mineral and bone disorder. On the other hand, APD
treatment inhibited focal bone resorption and increased
mineral content in the midshaft and distal femur by
influencing primarily bone regions with highest metabolic
activity, that is, the endocortical and trabecular surfaces. In
the femoral midshaft, the effect of APD on mineral content
and cortical cross-sectional area was particularly evident in
association with CRI.
MATERIALS AND METHODS
Animals and experimental design
Thirty-one 8-week-old, male Sprague–Dawley rats were randomly
assigned to surgical 5/6 nephrectomy (CRI) or unilateral nephrec-
tomy (Uni-Nx Control) (Figure 1). In the 5/6 nephrectomy
operation, the entire right kidney was removed along with upper
and lower thirds of the left kidney.49,50 Bisphosphonates have several
effects beyond those described for osteoclasts (bone resorption),
with potential influences on the cells of the immune system.51–54
Accordingly, to ascertain comparable inflammatory conditions in
the CRI and corresponding control rats, unilateral nephrectomy was
carried out in all Uni-Nx Control animals.
After 14 weeks of disease progression, the rats were allocated to
untreated (CRI) and treated (CRIþAPD) uremic groups, the latter
of which received APD (Aredia; Novartis, Switzerland) 3 mg/kg,
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subcutenaously, once weekly for the 8 weeks. The drug dose was
chosen on the basis of previous publications on APD treatment in
rat, in which the weekly dose has ranged from 0.5 to 10.5 mg/kg.55–57
The Uni-Nx-operated animals were allocated to untreated (Uni-Nx
Control) and treated (Uni-NxþAPD) groups. The rats in the
untreated groups received weekly injections of vehicle (0.9% NaCl
solution). To confirm that unilateral nephrectomy did not result in
development of renal insufficiency in the Uni-Nx Control rats,
plasma samples were also taken from 12 age-matched, normal
Sprague–Dawley rats (Control group).
All rats were housed two per cage with free access to water and
food. During the 14-week disease progression period, the rat chow
provided contained 0.9% calcium, 0.8% phosphate, 0.27% sodium,
and 1500 IU/kg vitamin D (Lactamin R34; AnalyCen, Linko¨ping,
Sweden). To sensitize rats to development of secondary hyperpar-
athyroidism, the calcium content of the chow was reduced to 0.3%
(modified Lactamin R34) after initiation of APD treatment, a dose
of calcium that we have shown previously to not result in detectable
changes of bone dimensions and strength in normal rats.20 The
experimental design of the study was approved by the Animal
Experimentation Committee of the University of Tampere, Finland.
The study conformed to the NIH Guide for the Care and Use of
Laboratory Animals.
Data collection and samples
The last APD injection was given 4–6 days preceding the sampling.
The bones were double fluorochrome labeled with subcutaneous
injection of tetracycline hydrochloride (25 mg/kg; Terramycin/LA;
Pfizer Ltd., Sandwich, UK) for 14 days and calcein (25 mg/kg;
Sigma Chemie GmbH, Deisenhof, Germany) 7 days before sacrifice.
All rats were killed and blood samples for creatinine, urea,
phosphate, parathyroid hormone, and calcitriol measurements were
analyzed.21,49,50 Plasma calcium could not be measured due to
technical reasons. Left femora were excised and placed in 70%
ethanol for histomorphometry, whereas right femora were stored at
20 1C in small Zip-Loc freezer bags wrapped in saline-soaked
gauze bandages for DXA, pQCT, and biomechanical testing. This
method of storage has been shown to preserve bone’s biomechanical
properties.58,59
Bone histomorphometry
The distal femoral metaphysis was dehydrated and embedded
without demineralization. The bones were sectioned at 5 mm and the
sections were stained with toluidine blue as described.60 An area of
7.5 mm2, immediately distal to the primary spongiosa and excluding
the cortical bone margins, was analyzed to obtain the following
cancellous bone measurements and calculated values as described:60
bone volume normalized to tissue volume (BV/TV, %), trabecular
thickness (Tb.Th, mm), trabecular number (Tb.N, 1/mm), trabecular
separation (Tb.Sp, mm), eroded surface (APD decreases osteoclast
activity) normalized to cancellous bone surface (ES/BS, %), oste-
oclast surface per bone surface (Oc.S/BS, %), osteoblast surface per
bone surface (Ob.S/BS, %), double labeled surface per bone surface
(dL.S/BS, %), mineral apposition rate (MAR, mm/day), bone
formation rate per bone surface (BFR/BS, mm2/mm/day), osteoid
volume normalized to bone volume (OV/BV, %), and tissue volume
(OV/TV, %), peritrabecular fibroblast lined bone surface normalized
to cancellous bone surface (Fb.S/BS). The histomorphometric
measurements were collected using the OsteoMeasure Analysis
System (OsteoMetrics, Atlanta, GA, USA).
DXA measurements
The DXA analysis (Norland XR-26; Norland Corp., Fort Atkinson,
WI, USA) of the femur was performed according to standard
procedure.61,62 The scanner was calibrated daily and performance
was controlled by quality assurance protocol.63 Pixel spacing was
0.5 0.5 mm and scan speed was 10 mm/s. For scanning, the femur
was placed in a constant location of the scan table on its posterior
surface. The baseline point was located on the soft tissue equivalent
and femur BMC was determined. In our laboratory, root mean-
square coefficient of variance64 for repeated measurements of BMC
of rat femur is 1.6%.61,62
Peripheral pQCT measurements
The cross-sections of the midshaft and distal femur were scanned
with a pQCT system (Stratec XCT Research M, software version
5.40B; Stratec Medizintechnik GmbH, Birkenfeld, Germany). The
bones were inserted with the shaft in axial direction and cross-
sectional slices from each bone were scanned at midshaft (a distance
of 50% of the femur length) and distal femur (a distance of 10% of
the femur length measured from the distal end). The voxel size was
0.070 0.070 0.5 mm3 and scan speed was 3 mm/s. Total BMC,
cBMD, total bone CSA, cortical area, and average cortical thickness
from the femoral midshaft, and CSA and BMC from distal femur
were determined. Our root mean-square coefficient of variance in
the femoral midshaft range between 0.6 and 1.5%.65
Dimensions
Dimensions of the femoral midshaft were measured with a digimatic
caliper. The length of femur was measured from the tip of the
greater trochanter to the intercondylar notch. The outer and inner
dimensions of the femoral midshaft were measured in the
orthogonal mediolateral and anteroposterior directions. Our root
mean-square coefficient of variance for repeated measurements of
femur dimensions range between 0.2 and 4.0%.61,62
Biomechanical testing
A material testing device (LR5K; JJ Lloyd Instruments,
Southampton, UK) was used for the anteroposterior three-point
bending of the femoral shafts.61,62 The femora were placed on their
posterior surface; the first support was placed just distal to the
trochanter minor and the second placed just proximal to the
condyles of femur. Then a bending load using a brass crossbar was
applied to the midshaft perpendicularly to the long axis of the bone
until failure of the specimen (breaking load). Our root mean-square
coefficient of variance of the breaking load for three-point bending
is 5%.66
Statistical analyses
Results are expressed as mean±s.e.m. All measurements were
blinded to the group assignments. Data were analyzed by two-way
factorial analysis of variance (2 2 study design) with renal status
(CRI) and pamidronate treatment (APD) as fixed factors, and
differences were considered significant when Po0.05. According to
the standard principles of the 2 2 study design, statistical
significance has been determined separately for the differences
between the individual treatment groups, for the main-effects of the
CRI and APD, and for the interaction. All data pertaining to
mechanical competence of the femur (cCSA, tBMC, tCSA, and Fmax)
were statistically controlled for body weight and femoral
length.65,67,68
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